UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

Source: 
Fierce Biotech
snippet: 

UCB Pharma has struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The takeover will give UCB control of a phase 3 rival to Alexion’s Soliris that some analysts have tipped to rack up blockbuster sales.